Anti-IL-19 antibody [EPNCIR168],Abcam,AB154187

This antibody was developed as part of a collaboration between the National Cancer Institute's Center for Cancer Research and the lab of Juergen Mueller. View antibodies from NCI Center for Cancer Research Collaboration . Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . Species reactivity Rat: We have preliminary internal testing data to indicate this antibody may not react with this species. Please contact us for more information.

Host

Rabbit

Reactivity

Mouse, Human

Application

ICC/IF, WB

Platform ID

BAB226712948

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Abcam

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Email:

[email protected]

Product Specifications
Scientific Background

Specifications

NameAnti-IL-19 antibody [EPNCIR168]
Cat. No.AB154187
HostRabbit
IsotypeIgG
ReactivityMouse, Human
ApplicationICC/IF, WB
ClonalityMonoclonal
Clone NumberEPNCIR168
ImmunogenThe exact immunogen used to generate this antibody is proprietary information.
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 50% Tissue culture supernatant, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Storage-20°C
Regulatory StatusResearch Use Only

Scientific Background

Target data Cytokine that functions as an anti-inflammatory and proangiogenic factor (PubMed : 34932373). Polarizes adaptive immunity to an anti-inflammatory phenotype through induction of T-helper 2 responses by both down-regulation of IFN-gamma and up-regulation of IL4 and IL13 (PubMed : 16365913). Produced by osteocytes, stimulates granulopoiesis and neutrophil formation (By similarity). Exerts its biological effect through a receptor complex consisting of a heterodimer of IL20RA and IL20RB (PubMed : 12351624). In turn, activates the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway, and importantly, STAT3 (PubMed : 11564763). See full target information IL19

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.